Finance

Granules India's Q3 profit falls on weak drug pricing in Europe

Published by Global Banking & Finance Review

Posted on January 24, 2025

2 min read

· Last updated: January 27, 2026

Add as preferred source on Google
Lawmaker Kim Leadbeater discusses UK's assisted dying law changes - Global Banking & Finance Review
Image of Kim Leadbeater addressing the media about proposed changes to the UK's assisted dying law, emphasizing the removal of High Court judge sign-off to enhance the legislative process.
Global Banking & Finance Awards 2026 — Call for Entries

(Reuters) - Granules India reported a drop in third-quarter profit on Friday, hurt by pricing pressure in its key European market. Consolidated profit fell to 1.18 billion rupees ($13.7 million) for

Granules India Sees Q3 Profit Drop Due to European Pricing

(Reuters) - Granules India reported a drop in third-quarter profit on Friday, hurt by pricing pressure in its key European market.

Consolidated profit fell to 1.18 billion rupees ($13.7 million) for the quarter ended Dec.31, from 1.26 billion rupees a year earlier.

Granules, which generates about two-thirds of its revenue from North America and 10% from Europe, posted a 1.5% fall in its revenue from operations.

Revenue from North America rose 16% year-on-year, while that from Europe declined 55%.

For further earnings highlights, click.

KEY CONTEXT

Granules, which holds a 30% share of the global paracetamol market, supplies the drug as an active pharmaceutical ingredient (API) and as a finished dosage form - ready for consumption - in Europe, Canada, and South Africa. APIs are the active and key components in a drug that produce the intended therapeutic effects.

Indian API makers have been grappling with weak pricing in key European and North American markets due to tough competition, even as global drugmakers turn to India to limit their reliance on Chinese contractors.

PEER COMPARISON

Estimates (next Analysts' sentiment

12 months)

RIC PE EV/EBIT Revenue Profit Mean # of Stock to Div

DA growth growth rating* analysts price yield

(%) (%) target** (%)

Granules India 23.85 13.60 11.75 27.90 Strong 4 0.89 0.25

Buy

Alivus Life 24.51 16.21 13.87 16.73 Strong 5 1.04 1.96

Sciences Buy

Laurus Labs 60.36 24.90 15.45 88.32 Hold 11 1.27 0.14

Divi's 61.78 43.44 16.77 28.45 Hold 21 1.10 0.52

Laboratories

* Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell

** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

OCTOBER TO DECEMBER STOCK PERFORMANCE

-- All data from LSEG

-- $1 = 86.1660 Indian rupees

(Reporting by Kashish Tandon in Bengaluru; Editing by Eileen Soreng)

Key Takeaways

  • Granules India's Q3 profit fell to 1.18 billion rupees.
  • European market pricing pressures impacted profits.
  • Revenue from North America increased by 16%.
  • Granules holds a 30% share of the global paracetamol market.
  • Indian API makers face tough competition in Europe and North America.

Frequently Asked Questions

What is the main topic?
The main topic is Granules India's Q3 profit decline due to weak drug pricing in Europe.
How did Granules India's North American revenue perform?
Granules India's revenue from North America rose by 16% year-on-year.
What challenges do Indian API makers face?
Indian API makers face weak pricing and tough competition in European and North American markets.

Related Articles

More from Finance

Explore more articles in the Finance category